Who Paid My Doc
Rafael Gonzalez
General Practice Miami, FL Medical Doctor
NPI 1487608840 CMS profile 21163
1479 Nw 27Th Ave, Miami, FL 33125
General payments
$292
Research payments
$722,343
Ownership & investment interest
$0
Research they led as principal investigator
$1,447,928
Through program year 2025, Rafael Gonzalez of Miami, FL is reported in the CMS Open Payments database as having received $292 across 8 general payments and $722,343 in research payments paid to them. Separately, studies naming them as principal investigator received $1,447,928 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $36 | 2 | |
| 2024 | General | $135 | 2 | |
| 2024 | Research | $332 | 1 | |
| 2023 | General | $34 | 1 | |
| 2023 | Research | $153,535 | 13 | |
| 2022 | General | $36 | 2 | |
| 2022 | Research | $121,070 | 18 | |
| 2021 | Research | $439,031 | 9 | |
| 2020 | Research | $8,375 | 2 | |
| 2019 | General | $51 | 1 |
Beside peers
- Rafael Gonzalez
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Rafael Gonzalez were reported at $36. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Rafael Gonzalez | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $51 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $0 | $93 | $30–$272 | $132 |
| 2022 | $36 | $103 | $36–$279 | $149 |
| 2023 | $34 | $106 | $34–$276 | $160 |
| 2024 | $135 | $114 | $39–$290 | $164 |
| 2025 | $36 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 205 drugsPart D claims
28,558
Drug cost
$781,384
Branded share of claims
16.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 137 | $78,595 | |
| Entresto Sacubitril/Valsartan | Brand | 106 | $71,067 | |
| Saxagliptin-Metformin Er Saxagliptin Hcl/Metformin Hcl | Brand | 180 | $62,993 | |
| Pregabalin | Generic | 399 | $29,548 | |
| Solifenacin Succinate | Generic | 137 | $29,311 | |
| Dapagliflozin Dapagliflozin Propanediol | Brand | 53 | $26,878 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 313 | $25,948 | |
| Dabigatran Etexilate Dabigatran Etexilate Mesylate | Brand | 180 | $22,935 | |
| Tadalafil | Generic | 189 | $20,995 | |
| Humalog Kwikpen U-100 Insulin Lispro | Brand | 93 | $17,216 |
The 10 drugs with the highest cost, of 205 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 30 billing codesPaid by Medicare
$90,856
Medicare patients
391
Services billed
1,017
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 63% | |
| Diabetes | 32% | |
| Depression | 32% | |
| COPD | 27% | |
| Chronic kidney disease | 25% | |
| Heart failure | 24% | |
| Arthritis | 19% | |
| Cancer | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
51 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other General Practice in Florida
Caley Castelein
General Practice · Miami Beach, FL
Robert Althar
General Practice · Pensacola, FL
Florencia Ziemke
General Practice · West Palm Beach, FL
Ausberto Hidalgo
General Practice · Pembroke Pines, FL
Ernesto Lamadrid
General Practice · Gainesville, FL
Idalia Acosta
General Practice · Miami, FL
Related records
General Practice in Florida
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.